08212017Headline:

Atlanta, Georgia

HomeGeorgiaAtlanta

Email M. Brandon Smith M. Brandon Smith on LinkedIn M. Brandon Smith on Avvo
M. Brandon Smith
M. Brandon Smith
Attorney • (800) 641-0098

CooperVision Contact Lens Recall Expanded With Reports of Serious Eye Injuries

Comments Off

An estimated 4.9 million contact lens have been voluntarily recalled by CooperVision because they may cause blurry vision, severe eye pain, and injuries that require medical treatment.

According to a news release by the company, the problem involves the level of silicone oil left on the lenses during the manufacturing process.

In August the company recalled close to 800,000 Avaira Toric lenses after the U.S. Food and Drug Administration (FDA) received dozens of reports of eye pain and vision problems.

The current recall, which involves Avaira Sphere contact lenses, was prompted after the FDA issued a Class I recall – the most stringent classification – about the products.

To date, the agency has received 40 reports of problems associated with CooperVision contact lenses. Fifteen of those reports mentioned Avaira Toric and at least two mentioned Avaira Sphere.

“Our first priority is always the health and safety of all CooperVision lens wearers and as such we responded quickly to complaints from our customers by initiating a voluntary recall” said Christine Moench, vice president, Global Regulatory Affairs and Quality Assurance. “We want to ensure that all consumers are aware of this action and know where to go for more information.”

To determine if you have the recalled contact lens, visit www.coopervision.com/recall and enter the lot number contained on your package. If your lot number is indeed affected, you should immediately discontinue use. The lens should be returned to the store of purchase or to the eye doctor who prescribed them.

Consumers that have experienced any problems associated with these products or have questions related to the recalls are urged to contact the company at 1-855-526-6737.

For more information regarding this recall, please visit the FDA Web site.